The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Role of endothelin in cardiovascular disease
Open accessAbstract
Endothelins are a family of peptides, which comprises endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3), each containing 21 amino-acids. ET-1 is a peptide secreted mostly by vascular endothelial cells, the predominant isoform expressed in vasculature and the most potent vasoconstrictor currently known. ET-1 also has inotropic, chemotactic and mitogenic properties. In addition, it influences salt and water homeostasis through its effects on the renin-angiotensin-aldosterone system (RAAS), vasopressin and atrial natriuretic peptide and stimulates the sympathetic nervous system. The overall action of endothelin is to increase blood pressure and vascular tone. Therefore, endothelin antagonists may play an important role in the treatment of cardiac, vascular and renal diseases associated with regional or systemic vasoconstriction and cell proliferation, such as essential hypertension, pulmonary hypertension, chronic heart failure and chronic renal failure. Long-term anti-endothelin therapy may improve symptoms and favourably alter the progression of heart failure. Endothelin appears to participate in induction and progression of sclerotic renal changes, leading to progression to end-stage renal disease. Anti-endothelin therapy might offer additional benefits in the prevention of progression of chronic renal failure in addition to the known benefits of RAAS inhibition. Clinical trials have demonstrated potentially important benefits of endothelin antagonists for patients with essential hypertension, pulmonary hypertension and heart failure. Further studies are necessary to determine the role of anti-endothelin therapy in the treatment of cardiovascular diseases and determine the different roles of selective receptor antagonism vs. mixed ET A/B-receptor antagonism in human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
Palmer, R. M. J., Ferrige, A. G., & Moncada, S. (1987) · Nature · doi:10.1038/327524a0 · Cited by 10,704 · cited 1×
“Prostacyclin and nitric oxide (NO) are potent vasodilators secreted by vascular endothelium.(1,2) The isolation of endothelium-derived vasodilators initiated a search for counterbalancing constricting factors (or EDCFs).”
Background
Cited by
Cellular and molecular mechanisms of kidney fibrosis
Djudjaj, S., & Boor, P. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.002 · Cited by 475
Proliferating Cholangiocytes: A Neuroendocrine Compartment in the Diseased Liver
Alvaro, D., Mancino, M. G., Glaser, S., Gaudio, E., Marzioni, M., Francis, H., & Alpini, G. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.07.023 · Cited by 304
Lasso peptides: structure, function, biosynthesis, and engineering
Maksimov, M. O., Pan, S. J., & James Link, A. (2012) · Natural Product Reports · doi:10.1039/c2np20070h · Cited by 279
Borovac, J. A., D'Amario, D., Bozic, J., & Glavas, D. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i8.373 · Cited by 195
Chen, Y., Zhang, H., Liu, H., Li, K., & Su, X. (2018) · Microvascular Research · doi:10.1016/j.mvr.2018.03.010 · Cited by 19
Metadata
- Authors
- Agapitov, A. V., & Haynes, W. G.
- Venue
- Journal of the Renin-Angiotensin-Aldosterone System
- Publisher
- SAGE Publications
- Published
- 2002-03
- Volume
- 3
- Issue
- 1
- Pages
- 1-15
- ISSN
- 1470-3203 (ISSN-L)
- 1752-8976
- OpenAlex
- W2110826092
- Cited by
- 185
- References
- 1
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of endothelin in cardiovascular disease. https://app.cochat.ai/papers/10.3317/jraas.2002.001
- The paper
- Agapitov, A. V., & Haynes, W. G. (2002). Role of endothelin in cardiovascular disease. Journal of the Renin-Angiotensin-Aldosterone System. https://doi.org/10.3317/jraas.2002.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.